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osting by EAbstract Exfoliation syndrome is a common cause of open-angle glaucoma. It is characterized by
microscopic ﬂakes of protein-rich material being deposited in both ocular and non-ocular tissues.
While its mechanism is poorly understood, family- and population-based studies have established
that the disorder has a strong genetic component. A further understanding of the relevant gene vari-
ants might help reveal the molecular mechanism behind exfoliation. The most-strongly associated
genetic variants are found in the lysyl oxidase-like 1 (LOXL1) gene. However, two major risk alleles
in the LOXL1 coding region are reversed between ethnic groups. It now appears the strong associ-
ation between LOXL1 and XFS is due to non-coding variants that have not yet been identiﬁed.
Such variants might alter LOXL1 expression, which is decreased in the late stages of exfoliation syn-
drome/glaucoma. Here we discuss LOXL1 as a risk gene for exfoliation syndrome and glaucoma.
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Exfoliation syndrome (XFS) is the most common identiﬁable
cause of open-angle glaucoma (Ritch, 1994). The resulting
glaucoma, termed exfoliation glaucoma (XFG), is a blinding
disorder characterized by whitish ﬂakes in the anterior cham-
ber of the eye, increased intraocular pressures, and optic nerve
damage. The clinical presentation of XFG has been described
in great detail in previous articles (Ritch and Schlotzer-Schre-
hardt, 2001; Vesti and Kivela, 2000). XFG currently carries a
worse prognosis than primary open-angle glaucoma (POAG).
XFG accounts for approximately 25% of open-angle glau-
coma worldwide and is more concentrated in certain regions
and ethnic groups (Ritch and Schlotzer-Schrehardt, 2001).
The risk of developing glaucoma in patients with XFS is in-
creased with longer duration. Approximately half of the eyes
with XFS will develop glaucoma within 15 years of diagnosis
(Jeng et al., 2007).
XFS is a systemic disorder that involves abnormal deposi-
tion of microscopic ﬁbrils in numerous ocular and non-ocular
tissues (Schlotzer-Schrehardt and Naumann, 2006). The etiol-
ogy of XFS is not fully understood but appears to be related to
the excessive production and abnormal crosslinking of elastic
ﬁbers (Schlotzer-Schrehardt, 2011). Deposition of these ﬁbers
is known to occur in the trabecular meshwork which likely
contributes to reduced facility of aqueous outﬂow, elevated
IOP, and can ultimately lead to the development of glaucoma
(Ritch et al., 2003). While the etiology of XFS/XFG remains
unknown, the disease appears to depend on risk genetic factors
around the lysyl oxidase-like 1 (LOXL1) gene. A full under-
standing of this association could be a powerful clue to the
pathology of XFS and its associated glaucoma.
2. XFS has complex inheritance pattern
XFS has a strong hereditary component. Family studies have
consistently supported a role for genetic factors XFS risk (All-
ingham et al., 2001; Damji et al., 1998; Forsman et al., 2007).
The pattern of inheritance is not clear however, and may be
due to late onset of disease and incomplete penetrance (Fors-
man et al., 2007). These factors make it difﬁcult to identify seg-
regation patterns in families. In addition to these factors there
may be important environmental factors involved in the path-
ogenesis of XFG/XFS (Challa, 2009).The prevalence of XFS/XFG is highly variable among dif-
ferent racial or ethnic groups. Rates in the Native American
Navajo population have been reported at 38% (Friederich,
1982). The Nordic populations have rates of XFS above
15% in individuals over 60 years of age (Arnarsson et al.,
2007). Some Arab and Greek populations have rates of XFS
above 25% in people over 70 (Summanen and Tonjum,
1988; Topouzis et al., 2007). The reports in Arabs also found
a signiﬁcant burden of XFS in younger groups, nearing 8%
in patients between ages 50 and 60 (Summanen and Tonjum,
1988). In contrast, XFS/XFG is rare among the West African
and Eskimo populations (Forsius, 1988; Ntim-Amponsah
et al., 2004). Although environmental factors may play a role
in XFS or XFG, it is interesting to note that African Ameri-
cans, largely descended from West African populations, also
share the low prevalence of XFS/XFG despite living in a re-
gion where the prevalence is substantially higher (Cashwell
and Shields, 1988).
3. Variants in LOXL1 associate with XFS
The lysyl oxidase-like 1 (LOXL1) gene was ﬁrst associated with
XFS/XFG in a genome-wide association study (GWAS)
(Thorleifsson et al., 2007). Three single-nucleotide polymor-
phisms (SNPs) were found to be highly associated with XFG
and later with XFS. All three SNPs were located within the
LOXL1 gene. One SNP, rs2165241, was located in intron 1
of LOXL1. The other two SNPs, rs1048661 and rs3825942,
were missense variants located in exon 1. For both coding
SNPs, the ‘G’ allele was associated with a higher risk of
XFS and XFG.
The relationship between the LOXL1 SNPs and XFS has
now been studied in numerous populations including Swedish
(Thorleifsson et al., 2007), US Caucasian (Aragon-Martin
et al., 2008; Challa et al., 2008; Fan et al., 2008; Fingert et
al., 2007; Yang et al., 2008), Australian (Hewitt et al., 2008),
German (Wolf et al., 2010), Italian (Pasutto et al., 2008), Cen-
tral European (Mossbock et al., 2008), Finnish (Lemmela
et al., 2009), Chinese (Chen et al., 2009; Lee et al., 2009),
Japanese (Fuse et al., 2008; Hayashi et al., 2008; Mabuchi et
al., 2008; Mori et al., 2008; Ozaki et al., 2008; Tanito et al.,
2008), Indian (Ramprasad et al., 2008), South African
(Rautenbach et al., 2011; Williams et al., 2010), and Saudi Ara-
bian (Abu-Amero et al., 2010). Observed SNP frequencies for
the two missense variants are shown in Table 1.
Table 1 Summary of the genetic association of two coding variants in LOXL1 gene with XFS/XFG.
Studied population rs1048661 ‘G’ allele Signiﬁcant
association
rs3825942 ‘G’ allele Signiﬁcant
association
References
Case Control Case Control
Icelandic 0.781 0.651 Yes 0.984 0.847 Yes Thorleifsson et al. (2007)
Swedish 0.834 0.682 Yes 0.995 0.879 Yes Thorleifsson et al. (2007)
American 0.819 0.600 Yes 0.986 0.880 Yes Fingert et al. (2007)
American 0.787 0.665 Yes 0.939 0.844 Yes Challa et al. (2008)
American NA NA NA 1.000 0.856 Yes Yang et al. (2008)
American 0.843 0.703 Yes 0.959 0.798 Yes Aragon-Martin et al. (2008)
American 0.829 0.719 No 0.988 0.795 Yes Fan et al. (2008)
Australian 0.78 0.660 Yes 0.95 0.84 Yes Hewitt et al. (2008)
Austrian 0.841 0.671 Yes 0.994 0.817 Yes Mossbock et al. (2008)
Germany 0.844 0.660 Yes 0.992 0.856 Yes Wolf et al. (2010)
Germany 0.818 0.644 Yes 0.951 0.857 Yes Pasutto et al. (2008)
Finnish 0.825 0.683 Yes 0.968 0.823 Yes Lemmela et al. (2009)
Italian 0.825 0.693 Yes 1.000 0.821 Yes Pasutto et al. (2008)
Saudi Arabian 0.876 0.762 Yes 0.968 0.817 Yes Abu-Amero et al. (2010)
Indian 0.721 0.634 No 0.923 0.742 Yes Ramprasad et al. (2008)
Chinese 0.542 0.444 No 0.992 0.918 Yes Lee et al. (2009)
Chinese 0.110 0.480 Yes 1.000 0.900 Yes Chen et al. (2009)
Japanese 0.036 0.493 Yes 1.000 0.877 Yes Fuse et al. (2008)
Japanese 0.008 0.460 Yes 1.000 0.857 Yes Hayashi et al. (2008)
Japanese 0.006 0.450 Yes 0.994 0.853 Yes Mabuchi et al. (2008)
Japanese 0.005 0.474 Yes 0.995 0.850 Yes Mori et al. (2008)
Japanese 0.005 0.497 Yes 0.986 0.863 Yes Ozaki et al. (2008)
Japanese 0.005 0.554 Yes 0.993 0.806 Yes Tanito et al. (2008)
South African 0.990 0.810 Yes 0.130 0.620 Yes Williams et al. (2010)
South African 1.000 0.883 Yes 0.140 0.617 Yes Rautenbach et al. (2011)
NA: not available; LOXL1: lysyl oxidase-like 1; XFS: exfoliation syndrome; XFG: exfoliation glaucoma.
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been largely consistent across all tested populations. However
there have been important exceptions. For example, the ‘G’ al-
lele for rs1048661 was not signiﬁcantly associated with XFG in
an Indian (Ramprasad et al., 2008) and Chinese (Lee et al.,
2009) population. Furthermore, the ‘G’ allele of rs1048661
was found to actually be protective in another Chinese popula-
tion (Chen et al., 2009) and several Japanese populations (Fuse
et al., 2008; Hayashi et al., 2008; Mabuchi et al., 2008; Mori
et al., 2008; Ozaki et al., 2008; Tanito et al., 2008). The incon-
sistent association between XFG and rs1048661 was also ob-
served for the intronic SNP, rs2165241 (Chen et al., 2010).
For this reason, it was concluded that this SNP is not a func-
tional variant for XFS/XFG.
The inconsistencies with rs1048661 and rs2165241 left the
third SNP, rs3825942, as the most promising functional candi-
dates for XFS. The rs3825942 SNP appeared to contribute to
XFS for two reasons. First, similar to rs1048661, the ‘G’ allele
for rs3825942 causes a missense change, G153D, in the
LOXL1 protein, a change that may have functional conse-
quences for the LOXL1 protein (Abu-Amero et al., 2010). Sec-
ond, the ‘G’ allele of rs3825942 was strongly, and consistently,
associated with XFS in a diverse set of populations. However,
recently two reports have found that the opposite ‘A’ allele for
rs3825942 is the risk allele in the South African black popula-
tion (Williams et al., 2010; Rautenbach et al., 2011). Given the
South African result, it now appears that rs3825942 does not
contribute to XFS. It now appears most likely that these SNPs
are in association with the actual functional allele (Williams
et al., 2010). The LOXL1 coding sequence has now been com-pletely sequenced in multiple populations with no consistent
risk alleles emerging (Abu-Amero et al., 2010; Williams
et al., 2010). Attention is now turning to non-coding, regula-
tory regions of LOXL1. These regions might contain func-
tional variants that contribute to XFS/XFG.4. Biochemical rationale for LOXL1 in XFS
Efforts have begun to understand how the pathogenesis of
XFS could be inﬂuenced by LOXL1. LOXL1 is a member of
the lysyl oxidase gene family, a group of enzymes involved in
the synthesis and maintenance of elastic ﬁbers (Csiszar, 2001;
Kagan and Li, 2003). LOXL1 appears to be particularly
important in the renewal of elastic tissues. This is supported
by LOXL1’s strong colocalization with elastin in vivo and also
by observations in LOXL1-knockout mice (Liu et al., 2004).
These mice develop multiple abnormalities of elastic tissue that
include lax skin, diverticula, enlarged airspaces, and prolapse
of the rectum and pelvis. Female mice lacking LOXL1 initially
have normal appearing elastic tissue; however, they are unable
to deposit new elastic tissues after pregnancy and birth. Collec-
tively, these data suggest that LOXL1 is responsible for tar-
geted renewal of elastic ﬁbers (Liu et al., 2004).
On a molecular level, LOXL1 appears to polymerize trop-
oelastin monomers into growing elastin polymers (Kagan
and Li, 2003; Liu et al., 2004). To accomplish this, LOXL1
is ﬁrst targeted to sites of elastogenesis by a pro-region located
near its N-terminus (Thomassin et al., 2005). LOXL1 is then
activated by removal of the pro-region by a proteinase. This
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of LOXL1. Once activated, LOXL1 deaminates lysine residues
in the tropoelastin molecule, allowing it to join the growing
elastin polymer.
From the genetic studies cited above, it now appears that
LOXL1 protein is involved in the pathogenesis of XFS, a dis-
order of elastic tissues (Schlotzer-Schrehardt, 2009). XFS ﬁ-
brils also contain additional proteins involved in elastic ﬁber
synthesis and structure (Ovodenko et al., 2007). In immunohis-
tochemistry studies, XFS ﬁbrils have been found to stain pos-
itively for the LOXL1 protein and its substrate tropoelastin
(Schlotzer-Schrehardt et al., 2008). Interestingly, an important
binding partner of LOXL1, ﬁbulin-5, was absent in PEX
deposits (Thomassin et al., 2005).
5. Altered LOXL1 expression is a possible pathological
mechanism
AlteredLOXL1 expressionmight contribute to the development
of XFS. Current evidence suggests that LOXL1 expression is al-
tered in XFG. In cadaveric ocular tissues, the expression of
LOXL1 was found increased in early-stage XFS but decreased
in late-stage XFS and in XFG (Schlotzer-Schrehardt et al.,
2008). Subsequent studies regarding the expression of LOXL1
in XFS/XFG have had mixed results (Khan et al., 2010; Mori
et al., 2008).
Several SNPs have been investigated for their effects on
LOXL1 expression. Both coding SNPs identiﬁed in the initial
GWAS were studied for effects on LOXL1 expression. The
coding SNP rs1048661 is associated with altered expression
of LOXL1. Its ‘G’ allele was associated with a 7.7% decrease
of LOXL1 expression in adipose tissue (Thorleifsson et al.,
2007) and approximately 20% in postmortem ocular tissue
(Schlotzer-Schrehardt et al., 2008). In contrast, the most
strongly associated SNP, rs3825942, was not associated with
a net increase or decrease of LOXL1 expression in adipose
or ocular tissue (Schlotzer-Schrehardt et al., 2008; Thorleifsson
et al., 2007).
Another SNP, rs16958477, was found to alter LOXL1
expression in vitro (Ferrell et al., 2009). This SNP is located
659 base pairs upstream of LOXL1. It appears to inﬂuence
the promoter activity of the one kilobase region upstream of
LOXL1. Its ‘C’ allele was associated with increased promoter
activity in a commercial plasmid. This SNP was originally
investigated for a connection to pelvic organ prolapse but no
signiﬁcant correlation was observed (Ferrell et al., 2009). The
SNP also did not associate with XFG in black South Africans
(Williams et al., 2010). The ‘A’ allele did associate with XFS in
a large Caucasian cohort with an OR 2.05 (1.54–2.72) (Jian
Fan et al., 2011). However, this association was much weaker
than rs3825942, which yielded an OR of 25 (8.3–50) in the
same cohort.
Collectively, these data leave several questions about the
role of expression in XFS and how to investigate it. First is
the odd situation that there is no recognized correlation be-
tween the most-strongly associated variant, rs3825942, and
LOXL1 expression. One possible explanation is that
rs3825942, and any variant in LD with rs3825942, might alter
expression patterns of LOXL1 without causing a net change of
mRNA levels. Such a scenario could relate to the repeated
observation that LOXL1 expression does not decrease untillate in the pathogenesis of XFS and might actually be in-
creased in early stages of XFS (Schlotzer-Schrehardt et al.,
2008).6. Other possible mechanisms for LOXL1 in XFS
The connection between LOXL1 and XFS could also possibly
result from another mechanism that does not center on expres-
sion. One possibility is that a variant in the LOXL1 region
could have an effect on LOXL1 splicing. Evidence now sup-
ports that a non-coding SNP can inﬂuence mRNA splicing
(Tazi et al., 2009). For example, the dopamine D2 receptor
gene carries two intronic SNPs that decrease the expression
of one splice product (Zhang et al., 2007). There is some evi-
dence to suggest that many GWAS associations for human
traits may be the result of splicing effects (Heinzen et al.,
2008). In the case of LOXL1, an intronic SNP might
alter LOXL1 splicing. The LOXL1 intronic sequence has not
been studied in previous reports, but it does contain at least
one SNP, rs2165241, that is strongly associated with XFS in
some populations (Jian Fan et al., 2011; Thorleifsson et al.,
2007).7. Other genes associated with XFS
Other genes appear to have a role in XFS and XFG. While
LOXL1 variants associate strongly with XFS, the high-risk al-
leles are often found in older unaffected individuals (Table 1).
This failure to develop XFS might partly result from other
genes that inﬂuence XFS pathogenesis. Several other genes
have been investigated. From these studies, a few possible pop-
ulation-speciﬁc risk factors have emerged (Schlotzer-Schre-
hardt, 2011).
A study in German patients looked at variants across six
genes that appear to have a functional role in the pathogenesis
of XFS (Krumbiegel et al., 2009). A total of 50 SNPs were
genotyped across these genes. Of the 50, only one SNP was
found to associate with XFS in the German cohort with an
OR of 1.34. The SNP was located in the 8th intron of the clus-
terin (CLU) gene. This one variant was then tested in a second
German cohort where it was still signiﬁcant. However, in an
Italian cohort, the SNP was not signiﬁcant (Krumbiegel
et al., 2009). It is possible that this allele has varying effects
based on ethnic background. Other genes have been investi-
gated because of a suspected role in the development of
XFS or transition from XFS to XFG (Schlotzer-Schrehardt,
2011). To date, most investigations have found negative re-
sults. Signiﬁcant associations have often been limited to stud-
ies in one population but not another (Schlotzer-Schrehardt,
2011).
A recent GWAS in German patients found an association
with variants of the CNTNAP2 gene with risk of exfoliation
(Krumbiegel et al., 2011). CNTNAP2 is a neuronal membrane
protein that is expressed in numerous ocular tissues involved in
XFS (Krumbiegel et al., 2011). This result was replicated in a
second German cohort, with a combined odds ratio (OR) of
about 1.4. However, CNTNAP2 was not associated with
XFS in an Italian cohort (Krumbiegel et al., 2011). Therefore,
it appears that CNTNAP2 may also be a population-speciﬁc
risk factor.
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Genetic screens for XFS are currently impractical due to the
low-speciﬁcity of known risk alleles (Challa, 2009). For in-
stance, in Caucasians, the rs3825942 risk allele has an 88% fre-
quency in controls (Fingert et al., 2007). Effective risk
screening will require the identiﬁcation of new risk variants,
either in the LOXL1 region or in other genes.
The LOXL1 region might carry more genetic information
to aid in risk stratiﬁcation. To date, most studies have focused
on the missense variants, which alone do not allow for mean-
ingful risk stratiﬁcation. However, it appears that the LOXL1
region contains other SNPs that confer risk of XFS indepen-
dently of the missense variants. For example, a promoter
SNP identiﬁed in US Caucasians was found to increase of risk
of XFS even when controlling for rs3825942 genotype (Jian
Fan et al., 2011).
An understanding of all genetic contributions to XFS, both
inside the LOXL1 region and in other genes, might allow for
improved risk stratiﬁcation. However, the impact of environ-
mental factors and the inﬂuence of random chance might limit
the predictive value of XFS risk variants. Only with a better
understanding of both genetic and environmental contribu-
tions could accurate risk stratiﬁcation be achieved. Even then,
a screen for risk-variants might only be cost-effective in certain
ethnicities.
Genetic insights might also aid in the treatment of XFG. A
mechanism to explain the LOXL1-XFG association could al-
low for new targets for intervention. For example, XFG pa-
tients might beneﬁt from increased LOXL1 expression since
they tend to have reduced expression in the eye (Khan et al.,
2010). More research might unveil additional targets for
molecular interventions.
9. Conclusions
The LOXL1 region contains variants that are strongly associ-
ated with XFS and XFG. Previous risk allele reversals ob-
served in Asian and African populations suggest that the
functional variants near LOXL1 have not been identiﬁed.
Identiﬁcation of the functional variants near LOXL1 will allow
for a comprehensive study of the mechanisms that underlie
XFS and XFG. Such knowledge might impact the diagnosis
and management of these conditions.References
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